SINGAPORE, Singapore, 2 December 2022 – MGI Tech Co. Ltd. (MGI), a company committed to building core tools and technologies to lead life science, today joins global and Asian cancer professionals at the ESMO Asia Congress 2022, taking place from 2–4 December in Singapore. At the event, MGI is also launching a free trial campaign for its latest sequencer, the DNBSEQ-G99*, for early users in APAC.
At ESMO Asia 2022, MGI will showcase its MGISP-100 Automated Sample Preparation System and the DNBSEQ-G99* Genetic Sequencer at Booth C209. Designed for small and medium-sized research laboratories, including hospital settings, the MGISP-100 offers automated library preparation for widely used applications such as breast cancer, lung cancer and other oncology panels.
One of the fastest medium-to-low throughput sequencers globally*, the DNBSEQ-G99* is built on MGI’s proprietary DNBSEQ™ technology and enhanced by innovations in biochemistry, optics, fluidics and temperature control. It is well suited for targeted oncology panel sequencing, oncology methylation sequencing and small whole-genome sequencing. The DNBSEQ-G99* will be available in Singapore from early 2023.
To allow customers to experience the speed and data quality of the DNBSEQ-G99*, MGI is offering free trials to early users in APAC from now until 31 January 2023. Each participating customer can receive up to 96 Gb of sequencing data at no cost. Visitors are invited to Booth C209 to learn more and see the DNBSEQ-G99* firsthand.
“We are excited to showcase our latest developments and connect with customers and partners at ESMO Asia Congress 2022,” said Dr Roy Tan, General Manager of MGI Asia Pacific. “MGI is committed to empowering scientific discovery and enabling clinical applications, not only in oncology, but also across drug discovery, precision medicine, precision prevention and treatment monitoring in Singapore and beyond.”
Earlier this year, MGI formed an official partnership with MiRXES, a Singapore-headquartered biotechnology company, to build an ultra-high-throughput, high-resolution spatial genomics pipeline in Singapore. The collaboration combines MiRXES’s end-to-end RNA translational research and molecular diagnostics expertise with MGI’s DNBSEQ-T10×4RS* sequencing system.
The DNBSEQ-T10×4RS* sequencing platform (T10), one of the world’s largest and highest throughput next-generation sequencers, was unveiled in late November in the presence of distinguished guests, including Dr Wang Jian, Chairman of MGI. Installed at MiRXES’s purpose-built multi-omics laboratory at Biopolis, the T10 is the first system of its kind operational in APAC outside of China. Through this installation, MGI aims to expand access to genomics and increase its impact across Singapore and the wider region.
In line with its commitment to Singapore’s healthcare ecosystem, MGI will also participate as a Gold Sponsor in The Singapore Healthcare AI Datathon and Expo, co-organised by the National University of Singapore (NUS), National University Health System (NUHS) and MIT Critical Data. MGI will host a workshop on 1 December covering its global deployments, tools and leading research projects. MGI technologies, including the ultra-high-throughput DNBSEQ-T7* sequencer, will also be exhibited on 2 December.
*For StandardMPS and CoolMPS: Unless otherwise stated, StandardMPS and CoolMPS sequencing reagents, and sequencers compatible with these reagents, are not available in Germany, Spain, the UK, Sweden, Belgium, Italy, Finland, the Czech Republic, Switzerland, Portugal, Austria and Romania. StandardMPS products are not available in Hong Kong. Purchase orders for StandardMPS products will not be accepted in the USA until after 1 January 2023.
